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Abstract 
Purpose. There is an urgent need to develop diagnostic tests to improve the 
detection of pathogens causing life-threatening infection (sepsis). SeptiFast is a CE-
marked multi-pathogen real-time PCR system capable of detecting DNA sequences 
of bacteria and fungi present in blood samples within a few hours. We report here a 
systematic review and meta-analysis of diagnostic accuracy studies of SeptiFast in 
the setting of suspected sepsis. 
Methods. A comprehensive search strategy was developed to identify studies that 
compared SeptiFast with blood culture in suspected sepsis. Methodological quality 
was assessed using QUADAS. Heterogeneity of studies was investigated using a 
coupled forest plot of sensitivity and specificity and a scatter plot in Receiver 
Operator Characteristic space. Bivariate model method was used to estimate 
summary sensitivity and specificity. 
Results. From 41 phase III diagnostic accuracy studies, summary sensitivity and 
specificity for SeptiFast compared with blood culture were 0.68 (95% CI 0.63-0.73) 
and 0.86 (95% CI 0.84-0.89) respectively. Study quality was judged to be variable 
with important deficiencies overall in design and reporting that could impact on 
derived diagnostic accuracy metrics. 
Conclusions. SeptiFast appears to have higher specificity than sensitivity, but 
deficiencies in study quality are likely to render this body of work unreliable. Based 
on the evidence presented here, it remains difficult to make firm recommendations 
about the likely clinical utility of SeptiFast in the setting of suspected sepsis. We 
recommend that future studies should include well designed and reported clinical 
diagnostic accuracy elements measured against all of the features of the STARD 
criteria to help inform the subsequent design of much needed interventional studies 
in the management of suspected sepsis.  
 
Word count: 225 241   
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Introduction 
While rapid identification and treatment of sepsis is associated with the best 
outcomes, sepsis can be difficult to diagnose and to differentiate from other common 
non-infectious causes of systemic inflammation including trauma, surgery and 
ischaemia-reperfusion [1]. Confirmation of sepsis, therefore, relies on objective 
diagnostic evidence for infection, including attempts to detect and identify live 
pathogens from blood samples by microbiological culture techniques [2, 3]. 
 
In the setting of sepsis, blood cultures do not always provide high diagnostic 
accuracy for infection in a timely manner, routinely taking several days before a 
positive result is available and are often negative [4]. The time between initial clinical 
suspicion and confirmation of infection, results in the early use of empirical broad 
spectrum antimicrobial drugs because treatment delay is associated with substantial 
increases in mortality [5-7]. Unnecessary and/or prolonged broad spectrum 
antimicrobial use is an inevitable consequence, which is associated with the 
development of drug resistant pathogens, Clostridium difficile infections, a range of 
avoidable adverse effects, as well as high costs [5]. An urgent global challenge has 
emerged [8], therefore, to develop techniques that could provide accurate diagnostic 
information within a short timeframe of clinical signs appearing and so allow more 
informed use of antibiotic therapy at an early stage. 
 
Real-time PCR technology can detect minute amounts of pathogen DNA in patient 
blood samples with results available within hours [9]. Laboratory validation studies 
have focused on two approaches using PCR for genomic amplification with either (a) 
broad range detection of bacterial or fungal DNA with universal primers, followed by 
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species identification using a post-PCR technique such as gene sequencing or 
electrospray mass spectrometry or (b) using species-specific hybridisation probes 
that provide direct confirmation of the species present [10]. While the laboratory 
analytical accuracy of these techniques for the detection of pathogen DNA in blood 
has been evaluated, there is a lack of reported clinical trial data to define the utility of 
such tests in patients [2, 10]. This has been due in part to the lack of standardised 
technology platforms that meet accepted regulatory standards for clinical diagnosis. 
 
SeptiFast, manufactured by Roche Diagnostics, GmbH, Mannheim, Germany and 
run on their real-time PCR instrument (the LightCycler®), was the first real-time PCR 
based system to be awarded a Conformité Européenne (CE) mark for simultaneous 
pathogen detection and identification in suspected bloodstream infection [11]. The 
system uses a multiplex approach, which allows detection of the most common 
pathogen species causing bloodstream infection in a single blood sample (Table 1). 
Identification of the pathogens is based on the use of species-specific probes 
targeting the internal transcribed spacer region between the 16S and 23S areas of 
ribosomal DNA of bacteria and between the 18S and 5.8S ribosomal regions of the 
fungal genome.  SeptiFast has been assessed at the laboratory level on clinical 
isolates and shown to have good analytical specificity and exclusivity, confirming its 
analytical validity [11]. Numerous clinical diagnostic studies have been reported 
since SeptiFast gained its CE-mark in 2006, predominantly focused on suspected 
sepsis. Chang and colleagues have reported a diagnostic accuracy systematic 
review of published full journal papers to 2012, with SeptiFast as the index test, but 
with various reference standards used to produce composite overall diagnostic 
accuracy metrics [12]. Based on their interpretation of the evidence presented, they 
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recommend that SeptiFast can be used to confidently diagnose bloodstream 
infection [12]. 
 
As part of a government commissioned Health Technology Assessment of SeptiFast 
in the United Kingdom [13], we report a more comprehensive diagnostic accuracy 
systematic review of SeptiFast focused on the setting of suspected sepsis and where 
blood cultures were used as the reference standard. This systematic review was 
piloted and registered with PROSPERO, the NIHR International Prospective Register 
of Systematic Reviews, in 2011 [14] and the study protocol was piloted and 
published in 2012 [15]. 
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Methods 
Inclusion criteria of studies: 
Participants 
Patients suspected of developing sepsis, including adults and children, who required 
blood cultures irrespective of where their care was being delivered, and including 
suspected community or hospital acquired infection. 
 
Target conditions 
Suspected sepsis, including severe sepsis and septic shock [16]. 
 
Index test 
LightCycler® SeptiFast as the index test on blood specimens for the detection and 
simultaneous identification of bacterial and fungal pathogens [11]. 
 
Comparator test (reference standard) 
Blood culture for the detection and identification of bloodstream bacterial and fungal 
pathogens was used as the reference test [4]. 
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Types of studies 
We included any clinical diagnostic accuracy study that compared the index real-time 
PCR test with standard culture results performed on a patient’s blood sample during 
the management of suspected sepsis. 
 
Search methods for identifying studies: 
Electronic searches 
We searched the Cochrane Database of Systematic Reviews, the Database of 
Abstracts of Reviews of Effects (DARE), the Health Technology Assessment 
Database (HTA), the NHS Economic Evaluation Database (NHSEED), The 
Cochrane Library, MEDLINE, EMBASE, ISI Web of Science, BIOSIS Previews, 
MEDION and the Aggressive Research Intelligence Facility database (ARIF). The 
CE mark for the index test was announced in January 2006; therefore, this 
systematic review only considered publications from this date in humans. There were 
no language restrictions in the electronic search for studies. 
 
Search terms/search strategy 
Specific search strategies were developed for each electronic database, 
commencing with MEDLINE (published previously) [14, 15]. The MEDLINE strategy 
was adapted for each subsequent database. All electronic searches were piloted 
prior to publication of our review protocol in 2012 and all searches were finally 
updated at the end of April 2014. 
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Other resources 
Backward tracking was performed by hand-searching the reference lists of all 
relevant articles uncovered from the electronic searches and forward tracking using 
the keyword ‘SeptiFast’ with ISI Citation Indices and Google Scholar and with a 
conference proceedings search using the Web of Science ISI Proceedings (from 
January 2006 to April 2014). We requested reference lists held by the only 
manufacturer of the index test (Roche Diagnostics) and requested any clinical 
diagnostic accuracy data collected by Roche Diagnostics to file for the CE mark. In 
addition, we searched for unpublished studies and ongoing trials involving the 
SeptiFast platform in the following online registers: http://www.nlm.nih.gov/hsrproj, 
http://www.controlled-trials.com/mrct/, http://portal.nihr.ac.uk/Pages/Portfolio.aspx 
and http://www.who.int/trialsearch, with identified corresponding authors of eligible 
trials and content experts contacted to identify potentially relevant studies and 
associated data. 
 
Data collection and analysis: 
Selection of studies (Salford, UK) 
The selection of titles and abstracts was conducted by review authors (CW, DG, KT 
and PD) using the inclusion criteria detailed above. The full papers of all abstracts 
deemed eligible (by any reviewer) were obtained and read to determine their 
inclusion in the review. Conference abstracts and journal correspondences were 
included if they met the inclusion criteria and the corresponding author was 
contacted to request any further information about their study or about full 
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publications in preparation. Conference abstracts were not included when reporting 
duplicate data contained in a subsequent paper. We resolved any disagreement for 
inclusion with discussion between the reviewers. 
 
Assessment of methodological quality (Belfast and Warwick, UK) 
Independent reviewers from Belfast (DM, RM, BB) and Warwick (GDP) assessed the 
quality of selected studies using a specific checklist, published previously [15] 
adapted from the QUADAS tool [17]. Each question on the checklist was answered 
with a yes/no response or noted as unclear if insufficient information was reported to 
enable a judgement to be made, and the reasons for the judgement made was 
documented. Review authors assessed methodological quality independently. Any 
subsequent discrepancies were then adjudicated and resolved by a systematic 
review methods expert (BB) and an infection diagnostic expert (RM). 
 
Data extraction  
A standard set of data was searched for and extracted where possible from each 
study using a tailored data extraction form (details published previously) [15] by 
review authors at Belfast and Warwick. Reviewers extracted data independently and 
any discrepancies were adjudicated and resolved by a systematic review methods 
expert (BB) and an infection diagnostic expert (RM). 
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Statistical analysis and data synthesis: 
Statistical analysis and data synthesis were planned and performed independently 
by a statistician (SG). Estimates of the combined sensitivity and specificity, with 95% 
confidence intervals, were made using Reitsma’s bivariate method [18].  Results 
were displayed as summary ROC plots, with 95% confidence regions and 95% 
prediction regions defined by Harbord as “the region within which, assuming the 
model is correct, we have 95% confidence that the true sensitivity and specificity of a 
future study should lie” [19]. An overall summary for all studies with useable data 
was produced, and subgroup analyses separating studies by: 
(a) Type of publication: full papers versus abstracts; 
(b) Age of participants: adult versus neonate/child (this analysis omitted studies 
where the population was mixed or unclear); 
(c) Hospital setting: emergency department versus other hospital setting, ICU 
versus other hospital setting (this analysis omitted studies where settings 
were mixed or unclear); 
(d) Co-morbidity: if sufficient data available to allow comparisons;  
(e) Commercial sponsorship: stated involvement of Roche Diagnostics versus no 
statement. 
 
For all subgroup analyses, summary ROC curves were produced with pooled 
estimates of sensitivity and specificity for each group, and tested whether the sub-
grouping explained a significant amount of additional variation using the difference in 
-2log likelihood statistics between the sub-grouped and overall models. 
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No attempts were made to quantify potential sources of study bias in this systematic 
review as the available methodologies have not been validated for use in relation to 
diagnostic test meta-analyses (http://srdta.cochrane.org/handbook-dta-reviews). 
 
Analyses were performed using SAS 9.3 (SAS Institute Inc. North Carolina, USA) and  
Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The 
Nordic Cochrane Centre, The Cochrane Collaboration, 2012. 
 
Results 
Study inclusion: 
We identified 2759 citations in total, of which 66 were considered potentially suitable 
(Figure 1). After full text review externally at Belfast and Warwick, and having 
contacted corresponding authors for any extra data in the case of conference 
abstracts and journal correspondences, 24 studies were excluded as it proved 
impossible to derive a 2 by 2 table to calculate required diagnostic metrics. In 
addition, one abstract was removed as the study data were co-reported in a full 
paper and another abstract was replaced by a full paper that was sent to us by the 
authors. In total, 41 studies were included in the final analysis (30 papers, 9 
conference abstracts and 2 correspondences - summarised in Table 2). 
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Study quality: 
Our independent external reviewers reported variable study quality and, although 
studies reported as full papers were associated with the best quality measures, there 
were important deficiencies overall in study design and reporting (Figure 2).  
Reviewers agreed that all of the studies selected aimed to compare test results from 
SeptiFast with blood culture and that the reported blood sampling for these tests was 
such that disease progression or regression bias would have been avoided. Blood 
culture, as the reference standard, appeared to have been applied to patients 
equally in a way that both partial (work-up) bias and verification bias were likely 
avoided. However the reference standard was not always adequately described, 
including blood sampling methods and the prevalence of defined contamination as a 
potential source of false positive culture results. Comparisons of the results of 
SeptiFast with blood culture at genus/species level were often difficult to adjudicate 
by reviewers, with no clear standards of reporting followed. The chance of 
misclassification when comparing the reference and index tests was therefore 
thought to be likely, impacting on the derived diagnostic accuracy metrics. In some 
studies, it was not clear how well the CE-marked protocol for SeptiFast had been 
followed, including how blood samples had been stored/handled prior to assay 
delivery. Assay failure rates were rarely reported. There was a universal lack of 
reported blinding of both reference standard and index tests such that reviewers 
believed that incorporation bias was highly likely. Overall, reviewers agreed that 
none of the included studies, as reported, met the Standards for Reporting 
Diagnostic Accuracy (STARD) criteria in full [62], and in some cases there were 
significant deficiencies (Figure 2). 
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Study characteristics and patient populations: 
Studies included patient cohorts from a wide range of age and settings (Table 2) 
representing a total of 7,727 patients contributing 10,493 episodes of suspected 
sepsis. The median prevalence of blood culture positivity in this group of patients 
was 17% (inter-quartile range 13-25%). Lack of uniform reporting made it difficult for 
reviewers to classify studies, with a variety of care settings, outcomes and alternative 
clinical reference standards reported alongside the direct comparison of SeptiFast 
with blood culture results. However, our external reviewers were able to identify age 
classes (neonate, child and adult), setting classes (emergency department, hospital 
setting, and intensive/critical care), commercial sponsorship (stated involvement of 
Roche Diagnostics or no statement) and a group of studies that focused on 
haemato-oncology patients. In addition, studies were assigned a diagnostic evidence 
level III [20] in each case. 
 
Estimated summary diagnostic accuracy of SeptiFast: 
Figure 3 shows the coupled forest plots of sensitivity and specificity for each study 
and Figure 4 displays the scatter plot in ROC space (plotting sensitivity against 1 - 
specificity for each study). Summary sensitivity and specificity for SeptiFast 
compared with blood culture, estimated using the bivariate model method, were 0.68 
(95% CI 0.63-0.73) and 0.86 (95% CI 0.84-0.89) respectively, suggesting that a 
positive blood test at genus/species level returned by SeptiFast in the setting of a 
patient with suspected sepsis could have higher diagnostic value (rule-in) than a 
negative test result (rule-out) when compared with blood culture.  
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Exploration of subgroups: 
Subgroups were investigated and estimated pooled diagnostic accuracy metrics 
produced for each group. Table 3 summaries these results and shows that in each 
case sub-grouping did not explain any significant amount of additional variation in 
sensitivity or specificity when compared with the overall models. There were 
insufficient studies reporting solely in paediatric populations to allow analysis. 
 
Discussion 
Our comprehensive systematic review was designed to help understand the 
estimated combined diagnostic accuracy of SeptiFast in detecting and identifying 
bacterial and fungal pathogens in the blood of patients with suspected sepsis. We 
included 41 studies reporting on a total of 10,493 SeptiFast tests when compared 
with blood culture. 
 
Estimated combined results for sensitivity and specificity suggested that SeptiFast 
has a higher specificity than sensitivity. For the healthcare team, this implies that 
positive blood tests returned by SeptiFast at pathogen genus/species level could 
have higher diagnostic utility  (as a rapid rule-in test) than negative results (as a 
rapid rule-out test), at least when compared with blood culture. The apparent 
confidence in this statement is greater for specificity than sensitivity (Figures 3 and 
4) because the median event rate of 17% BC positivity for the studies means that the 
majority of reference tests performed was negative. 
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The clinical interpretation of these overall diagnostic accuracy results is that negative 
SeptiFast tests could reasonably be false-negatives (expressed as a low overall 
diagnostic sensitivity), explained in part by pathogens detected in blood culture that 
were not on the PCR test panel. In the future, this could suggest that developing 
molecular tests that incorporate wider test panels of pathogens may be expected to 
provide greater diagnostic sensitivity (fewer false negative results) giving clinicians 
greater confidence in a rapid negative test result.   In addition, despite a higher 
estimated overall specificity, when compared with sensitivity, the upper confidence 
interval did not reach 90%. Specificity of SeptiFast, when compared with culture, will 
be limited by the presence of false positive results – a positive PCR in the setting of 
a negative blood culture. In some studies [40,41], a proportion of these false-positive 
results were reported to be concordant with culture positivity from samples other 
than blood, suggesting that in some cases of suspected sepsis a positive SeptiFast 
result may reflect infection not detectable by blood culture. However, overall, there 
are no clear explanations for all of these false-positive and false-negative SeptiFast 
results because no systematic investigation has been undertaken linking laboratory 
performance with clinical diagnostic accuracy. In addition, it remains extremely 
difficult to speculate what implications these diagnostic accuracy results may have 
for direct clinical care because SeptiFast does not report antibiotic sensitivity data 
(other than identifying the MecA gene confirming meticillin resistance following 
detection of S. aureus [11]) and there have been no systematic interventional clinical 
trials reported to date on the efficacy and overall impact on clinical, laboratory and 
cost effectiveness of supplementing or replacing blood culture with SeptiFast. 
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All diagnostic metrics were reported using blood culture as the reference standard 
because this formed the basis of both the original laboratory diagnostic validity 
studies for SeptiFast [11] and the subsequent body of clinical diagnostic accuracy 
studies reported here. However, we accept that there could be limitations to this 
standard, particularly in the setting of intercurrent antimicrobial therapy. While 
antibiotic exposure data were rarely reported in the included studies, it is likely, for 
example, that patients in intensive care units were likely already exposed to broad 
spectrum antibiotics [33]. It is interesting to note that included studies recruiting 
solely from intensive care appeared to have slightly worse diagnostic metrics (both 
sensitivity, with higher rates of false negatives; and specificity, with higher rates of 
false positives) when compared with the results of blood culture (Table 3), but not to 
a significant level. Antimicrobial exposure is not the only factor that will distinguish 
patients in intensive care from other hospitalised patients, but it does seem 
particularly pertinent because of the widespread use of blood culture as the 
reference standard in these studies. The potential impact of antimicrobials in 
producing positive PCR tests with blood and associated negative blood culture 
results (false positives in our analysis) leads one to question blood culture as a 
relevant reference standard and challenges clinicians to consider a positive PCR test 
in this setting as a true positive, providing additional diagnostic information in 
patients with suspected sepsis. However, explaining the potential impact of 
antimicrobials on increasing false negative PCR tests (i.e. where associated blood 
culture tests are positive) is more problematic. In practice, a wide range of factors 
are known to influence the diagnostic accuracy of blood cultures [4] and, in our view, 
it is important to develop further and adopt statistical techniques that avoid the need 
for comparison to a single reference standard to provide a more meaningful estimate 
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of the clinical reliability of emerging molecular diagnostic tests [63]. However, to 
achieve this aim, diagnostic studies must be designed and reported to accepted 
international standards [62]. 
 
However, we do not know the full extent of this problem or indeed whether studies 
have deliberately included or excluded such patients. In addition, SeptiFast was 
developed to simultaneously detect and identify a panel of the most common 
pathogens based on reported international blood culture surveillance data [11]. 
Therefore, in the absence of an internationally agreed approach to an alternative 
reference standard for pathogen detection from blood samples at present, we 
believe that a culture-based reference standard provided the most robust approach 
for this review. 
 
During the implementation of our review, another systematic review has reported on 
the diagnostic accuracy performance of SeptiFast [12]. Chang and colleagues 
synthesised improved overall diagnostic accuracy metrics for SeptiFast when 
compared with our own review: sensitivity 0.75 (95% CI: 0.65-0.83) vs 0.68 (95% CI 
0.63-0.73) and specificity 0.92 (95%CI: 0.90-0.95) vs 0.86 (95% CI 0.84-0.89) 
respectively. However, there were important differences between our reviews. 
Chang used a basic keyword search strategy (ending in 2012) for journal papers 
only, risking publication bias. We used a systematic and comprehensive search 
strategy that aimed to avoid any publication bias. Chang reports SeptiFast results 
against various reference standards to produce composite overall diagnostic 
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accuracy metrics. We report overall diagnostic accuracy metrics from the results of 
SeptiFast measured against blood culture. These factors may have contributed to 
inflate the overall diagnostic accuracy metrics for SeptiFast reported by Chang when 
compared with the results of our own systematic review. 
 
Diagnostic accuracy studies included in our review were performed within the 
challenging care environments for patients with suspected sepsis. Clinical diagnostic 
accuracy studies, in general, are difficult to perform well and often fall short in terms 
of study quality. Our independent reviewers found significant deficiencies when 
assessing the quality of design and reporting for studies incorporating SeptiFast as 
the index test. For both papers and abstracts, the application of reference and index 
tests were the only elements that were reported consistently, raising significant 
concern about the possible effects of numerous sources of bias on the derived 
summary estimates of SeptiFast test performance. Indeed, the 95% prediction region 
in ROC space in Figure 4 shows considerable uncertainty about the likely true 
sensitivity and specificity of a future study. Therefore, despite the considerable 
international effort in determining the likely diagnostic accuracy of SeptiFast in the 
setting of suspected sepsis, we are not confident in the current body of evidence 
because of the overall weaknesses in study design and reporting outlined in our 
review. Based on these findings, we do not agree with Chang and colleagues who 
state that “in the presence of a positive SeptiFast result in a patient with suspected 
bacterial or fungal sepsis, a clinician can confidently diagnose bacteremia or 
fungemia and begin appropriate antimicrobial therapy, while forgoing unnecessary 
additional diagnostic testing” [12]. For example, in a high prevalence population, 
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such as a patient admitted to intensive care with septic shock, broad spectrum 
antibiotics should have been delivered quickly, well before the results of blood 
culture (or indeed SeptiFast) will be available [2]. In this setting, the pre-test 
probability for circulating pathogens is likely high and there is an increased chance of 
delivering positive SeptiFast and blood culture tests, particularly if blood is sampled 
before antimicrobial treatment commences. Delivering a positive SeptiFast test 
ahead of a blood culture result in this setting might help the intensive care clinician 
consider early antibiotic de-escalation based on the detected pathogen species. 
However, SeptiFast does not provide comprehensive antimicrobial susceptibility 
information and crucial clinical decisions based only on pathogen species may be 
unwise in this setting and, as described previously, remains untested in carefully 
controlled clinical trials.  Furthermore, In addition, we do not agree with Chang and 
colleagues that returning a negative SeptiFast result, even in a low prevalence 
population, “may justify withholding antibiotics” [12]. For example, a patient admitted 
to an emergency department with clinical features of sepsis, in the absence of 
circulatory compromise or organ dysfunction, is likely to have a low pre-test 
probability for circulating pathogen. Delivering a negative SeptiFast test to the clinical 
team over the subsequent hours may provide some confidence in excluding serious 
infection as the cause of symptoms. However, given the high rate of false-negative 
SeptiFast tests identified in our review, the clinician is not completely confident and 
could miss some cases of bacteraemia and other infections outside the circulation. 
Based on the evidence presented here, we are concerned that clinical decisions 
about treatment interventions/adjustments (notably antimicrobial chemotherapy) 
based on SeptiFast results, potentially delivered within hours of the suspicion of 
sepsis, could expose patients to risk because inadequately managed sepsis is 
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associated with high mortality and rapid appropriate antimicrobial choices are crucial 
for survival [2]. 
 
Our views, evidenced by the present systematic review, supports current 
international guidelines on diagnosis and treatment of sepsis which indicate that 
there is limited clinical experience with non-culture-based diagnostic methods, such 
as SeptiFast, and that more high-quality clinical studies are needed before any firm 
recommendations can be made about their potential utility [2]. We recommend that 
future clinical studies incorporating SeptiFast, or any other novel infection/sepsis 
diagnostic, should include well designed and reported clinical diagnostic accuracy 
elements measured against all of the features of the STARD criteria [62]. Much 
needed clinical intervention studies in the setting of suspected sepsis remain difficult 
to design and justify until higher quality clinical diagnostic accuracy evidence is 
available.  
 
Manuscript word count: 3,829 3,313 
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Table 1: Pathogens detectable using LightCycler® SeptiFast test 
Gram-negative bacteria Gram-positive bacteria Fungi 
 
Escherichia coli  
 
Staphylococcus aureus 
 
Candida albicans 
Klebsiella 
(pneumoniae/oxytoca) 
Coagulase-negative 
staphylococci*  
 
Candida tropicalis 
Serratia marcescens Streptococcus pneumonia Candida parapsilosis 
Enterobacter 
(cloacae/aerogenes) 
 
Streptococcus spp.
# Candida glabrata 
Proteus mirabilis Enterococcus faecium Candida krusei 
Acinetobacter baumanni Enterococcus faecalis Aspergillus fumigatus 
Pseudomonas aeruginosa   
Stentrophomonas maltophilia   
   
*Single probe detects a group of staphylococcal pathogens including S. epidermidis, S. haemolyticus# 
Single probe detects a group of streptococcal pathogens including S. pyogenes, S. agalacticae, S. 
mitis  
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Table 2: Summary of studies included in review. # indicates haemato-oncology study cohorts. 
First author Year Manuscript type Study 
country 
Patient setting Age 
category 
Diagnostic 
study 
evidence 
level20 
Number of patients Number of paired 
blood tests 
Bacteraemia 
prevalence (%) 
Raglio [21] 2006 Abstract Not stated Not stated Not stated III 74 114 15 
Klemm [22] 2007 Abstract Germany Intensive/Critical Care Not stated III 44 56 37 
Bingold [23] 2007 Abstract Germany Intensive/Critical Care Not stated III 21 134 15 
Vince [24] 2008 Correspondence Croatia In hospital and 
Intensive/Critical Care 
Not stated III 36 39 21 
Mancini [25] 2008 Paper Italy In hospital and unclear 
if Intensive/Critical Care 
# 
Adults III 34 103 20 
Louie [26] 2008 Paper USA Emergency 
Department, In hospital 
and Intensive/Critical 
Care 
Adults III 200 200 21 
Lodes [27] 2008 Abstract Germany Intensive/Critical Care Not stated III 137 358 13 
Westh [28] 2009 Paper Germany Not stated Not stated III 359 558 13 
Varani [29] 2009 Paper Italy In hospital and unclear 
if Intensive/Critical Care 
# 
Adults and 
children 
III 100 130 29 
Palomares [30] 2009 Abstract Spain Intensive/Critical Care Not stated III 73 76 13 
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Lodes [31] 2009 Paper Germany Intensive/Critical Care Adults III 52 258 12 
Dierkes [32] 2009 Paper Germany Intensive/Critical Care Adults III 77 99 23 
Dark [33] 2009 Correspondence UK Intensive/Critical Care Adults III 50 90 12 
Yanagihara [34] 2010 Paper Japan In hospital and 
Emergency Department 
Not stated III 212 400 8 
Wallet [35] 2010 Paper France Intensive/Critical Care Adults III 72 102 10 
Tsalik [36] 2010 Paper USA Emergency Department Adults III 306 306 22 
S'oki [37] 2010 Abstract Hungary In hospital and 
Intensive/Critical Care 
Not stated III 159 162 24 
Regueiro [38] 2010 Paper Spain In hospital and 
Intensive/Critical Care 
Adults III 72 106 25 
Maubon [39] 2010 Paper France In hospital and unclear 
if Intensive/Critical Care 
# 
Not stated III 110 110 29 
Lehmann [40] 2010 Paper Germany Intensive/Critical Care Adults III 108 453 13 
Bloos [41] 2010 Paper Germany, 
France 
Intensive/Critical Care Adult III 142 236 17 
Berger [42] 2010 Abstract Austria Neonatal Unit Neonates III 38 38 45 
Avolio [43] 2010 Paper Italy Emergency Department Adult III 144 144 30 
Vrioni [44] 2011 Abstract Greece Not stated Not stated III 33 33 24 
Sitnik [45] 2011 Abstract Brazil Intensive/Critical Care Not stated III 114 114 14 
24 
 
 
Obara [46] 2011 Paper Japan Emergency 
Department, In hospital 
and Intensive/Critical 
Care 
Adults III 54 78 15 
Lucignano [47] 2011 Paper Italy In hospital and 
Intensive/Critical Care 
Neonates 
and 
children 
III 811 1553 10 
Josefson [48] 2011 Paper Sweden In hospital Adults and 
children 
III 1093 1141 12 
Hettwer [49] 2011 Paper Germany Emergency Department Adults III 153 113 45 
Bravo [50] 2011 Paper Spain In hospital and 
Intensive/Critical Care 
Adult III 53 53 47 
Tschiedel [51] 2012 Paper Germany In hospital and 
Intensive/Critical Care 
Adults and 
children 
III 75 110 17 
Rath [52] 2012 Paper Germany Intensive/Critical Care Adults III 170 225 36 
Pasqualini [53] 2012 Paper Italy In hospital and unclear 
if Intensive/Critical Care 
Not stated III 391 391 15 
Mauro [54] 2012 Paper Italy In hospital and unclear 
if Intensive/Critical Care 
# 
Adult and 
children 
III 79 79 41 
Lodes [55] 2012 Paper Germany Intensive/Critical Care Adults III 104 148 20 
Guido [56] 2012 Paper Italy In hospital and unclear 
if Intensive/Critical Care 
# 
Adults III 166 166 14 
25 
 
 
Grif [57] 2012 Paper Austria In hospital and 
Intensive/Critical Care 
Not stated III 61 71 7 
Leitner [58] 2013 Paper Austria Not stated Not stated III 57 75 15 
Herne [59] 2013 Paper Estonia In hospital and 
Intensive/Critical Care 
Adults III 144 160 21 
Burdino [60] 2014 Paper Italy In hospital and 
Intensive/Critical Care 
Adults III 1024 1186 15 
Avolio [61] 2014 Paper Italy Emergency Department  
and Intensive/Critical 
Care 
Adults III 525 525 25 
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Subgroup 
 
Sensitivity 
(95% CI) 
 
Specificity 
(95% CI) 
 
Interaction test for 
subgroup differences 
            χ
2                                         
p
 
Papers 0.67 (0.62-0.73) 0.88 (0.85-0.90)  
4.3 
 
0.12 Abstracts 0.69 (0.58-0.78) 0.81 (0.75-0.87) 
Emergency Department 0.69 (0.52-0.83) 0.93 (0.86-0.96)  
3.2 
 
0.19 Other hospital setting 0.67 (0.61-0.72) 0.86 (0.83-0.89) 
ICU 0.64 (0.54-0.74) 0.83 (0.78-0.86)  
5.8 
 
0.06 Other hospital setting 0.68 (0.54-0.80) 0.89 (0.85-0.93) 
Haemato-oncology 0.66 (0.61-0.71) 0.86 (0.84-0.89)  
2.7 
 
0.26 All other patient groups 0.78 (0.64-0.87) 0.88 (0.79-0.93) 
Stated Roche 
involvement 
0.68 (0.61-0.75) 0.88 (0.85-0.91)  
2.1 
 
0.35 
Not stated 0.67 (0.61-0.73) 0.85 (0.81-0.88) 
 
 
Table 3: Planned sub-group analyses.  
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Figure 1: Flow diagram of study selection 
 
28 
 
 
 
 
 
Figure 2: Summary of independent review of quality of included studies. (Green = yes, yellow = uncertain and red = no)
29 
 
 
 
 
 
Figure 3: Forest plot of included studies 
30 
 
 
 
 
Figure 4: Summary Receiver Operator Curve (ROC), with 95% confidence region 
(dotted) and 95% prediction region (dashed) 
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